Equibles does not estimate personal net worth.
Earlier roles on record: Chief Accounting Officer at Ocugen, Inc. (OCGN) until March 10, 2023. Ocugen, Inc. reported in an 8-K filed March 10, 2023 that Jessica Crespo resigned as Chief Accounting Officer and principal accounting officer, effective March 10, 2023. Jessica Crespo has spoken on 4 earnings calls across 1 company, most recently for Ocugen, Inc. on February 28, 2023. The companies whose calls Jessica Crespo spoke on are classified in the Healthcare sector.
“On March 7, 2023, Jessica Crespo, Chief Accounting Officer and principal accounting officer of Ocugen, Inc. (the "Company"), tendered her resignation to the Company, effective as of March 10, 2023 (the "Effective Date"), in order to pursue new opportunities.”
“I will now provide a brief overview of our key financial results for the fourth quarter and full year 2022. Our research and development expenses for the quarter ended December 31, 2022, were $17.2 million compared to $7.1 million for the fourth quarter of 2021.”
“I'll now provide an overview of the key financial results for the third quarter of 2022. Our research and development expenses for the three months ended September 30, 2022, were $15.6 million compared to $6.3 million for the three months ended September 30, 2021.”
“I will now provide an overview of the key financial results for the second quarter of 2022. Our research and development expenses for the quarter ended June 30, 2022 were $9 million compared to $18.9 million for the quarter ended June 30, 2021.”
“I will now provide an overview of our key financial results for the first quarter of 2022. Our research and development expenses for the three months ended March 31, 2022, were $7.9 million, compared to $2.9 million for the quarter ended March 31, 2021.”
Start not stated–2023-03-10
OCGN
Biotechnology · Healthcare
Chief Accounting Officer
